Aripiprazole
Product Images NDC 68071-2705

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-2705). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2705 3)

Aripiprazole 5mg tablet label from NuCare Pharmaceuticals, Inc. The label shows package size of 30 tablets, with NDC 68071-2705-3. It includes manufacturing information by Alkerm Laboratories Ltd., Mumbai, India, and NuCare Pharmaceuticals, Inc., Orange, CA. The label also features prescription-only status, storage instructions (68-77°F), and a warning to keep out of reach of children.*

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

Kaplan-Meier plot comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The graph includes the number of subjects at risk at various time points along the study period, with Aripiprazole shown by a solid line and placebo by a dashed line.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing dehydro-aripiprazole fold change and 90% confidence intervals with various inhibitors and other drugs. The x-axis represents change relative to reference without interacting drug, while the y-axis lists CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducer, gastric acid blockers, and other drugs. Data points indicate changes in AUC and Cmax values.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot chart showing fold change and 90% confidence intervals for various drugs and their pharmacokinetic parameters (Cmax, AUC, INR, DMVDRP) relative to a reference without an interacting drug. Listed drugs include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (parent and O-desmethyl metabolite), and escitalopram, with corresponding pharmacokinetic measures for each.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic bar plot illustrating aripiprazole fold change and 90% confidence intervals across various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis shows change relative to reference from 0.5 to 3.0, with separate bars for AUC and Cmax values for each factor.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A pharmacokinetic forest plot titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing changes in AUC and Cmax relative to reference across factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severities, and severe renal impairment. Horizontal lines represent 90% confidence intervals for fold changes.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the change relative to reference in AUC and Cmax metrics when Aripiprazole is administered with various inhibitors and blockers, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, and gastric acid blocker famotidine, as well as other drugs like valproate, lithium, and lorazepam. The chart indicates fold changes with error bars representing 90% confidence intervals.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of the active ingredient aripiprazole, showing its molecular layout with chlorine atoms, piperazine ring, and quinolinone moiety.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve chart comparing the proportion of subjects experiencing relapse over days from randomization between Aripiprazole and placebo groups. The curve for Aripiprazole shows a lower proportion with relapse than placebo over the 182-day period, with the number of subjects at risk listed below the x-axis for both groups at multiple time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.